T-cell-receptor-like antibodies - Generation, function and applications

Expert Reviews in Molecular Medicine

Volumn 14, Issue , 2012, Pages

  Dahan, Rony ^a   Reiter, Yoram ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; DENDRITIC CELL VACCINE; EPITOPE; HLA A24 ANTIGEN; IMMUNOTOXIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; RECEPTOR ANTIBODY; RITUXIMAB; T LYMPHOCYTE RECEPTOR LIKE ANTIBODY; TRASTUZUMAB; TUMOR ANTIGEN; UNCLASSIFIED DRUG; HLA ANTIGEN CLASS 1; LYMPHOCYTE ANTIGEN RECEPTOR; PEPTIDE; TUMOR PROTEIN; VIRUS ANTIGEN; VIRUS PROTEIN;

ADOPTIVE TRANSFER; ANTIBODY AFFINITY; ANTIBODY LIBRARY; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; BREAST TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; COLORECTAL CANCER; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; EPSTEIN BARR VIRUS INFECTION; HEMATOLOGIC MALIGNANCY; HEPATITIS C; HERPES SIMPLEX; HLA SYSTEM; HUMAN; HYBRIDOMA; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; METASTASIS; MOLECULAR CLONING; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROSTATE TUMOR; REVIEW; SOLID TUMOR; TUMOR IMMUNITY; ANIMAL; CELL TRANSFORMATION; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; NEOPLASM; PATHOLOGY; VIRUS INFECTION;

ANIMALS; ANTIBODY AFFINITY; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; ANTIGENS, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; CELL TRANSFORMATION, NEOPLASTIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOTHERAPY; NEOPLASM PROTEINS; NEOPLASMS; PEPTIDES; RECEPTORS, ANTIGEN, T-CELL; VIRAL PROTEINS; VIRUS DISEASES;

EID: 84859068537     PISSN: 14623994     EISSN: None     Source Type: Journal    
DOI: 10.1017/erm.2012.2     Document Type: Review

References (84)

1. Novellino, L., Castelli, C. and Parmiani, G. (2005) A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunology, Immunotherapy 54, 187-207 (Pubitemid 40174238)
2. Rosenberg, S.A. (2001) Progress in human tumour immunology and immunotherapy. Nature 411, 380-384 (Pubitemid 32467048)
3. Morin, P.J. et al. (1997) Activation of 2-catenin-Tcf signaling in colon cancer by mutations in 2-catenin or APC. Science 275, 1787-1790 (Pubitemid 27136715)
4. de Vries, T.J. et al. (1997) Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions. Cancer Research 57, 3223-3229 (Pubitemid 27351739)
5. Sugita, Y. et al. (2004) NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors. Cancer Research 64, 2199-2204 (Pubitemid 38339473)
6. Nakada, T. et al. (2003) NY-ESO-1mRNAexpression and immunogenicity in adVanced prostate cancer. Cancer Immunity 3, 10
7. Schechter, A.L. et al. (1984) The neu oncogene: An erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 312, 513-516 (Pubitemid 15182278)
8. King, C.R., Kraus, M.H. and Aaronson, S.A. (1985) Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229, 974-976 (Pubitemid 16248488)
9. Shetty, V. et al. (2011) MHC class I-presented lung cancer-associated tumor antigens identified by immunoproteomics analysis are targets for cancerspecific T cell response. Journal of Proteomics 74, 728-743
10. Coulie, P.G. et al. (1994) A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. Journal of Experimental Medicine 180, 35-42 (Pubitemid 24181053)
11. Nagaraj, S. and Gabrilovich, D.I. (2008) Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Research 68, 2561-2563 (Pubitemid 351556251)
12. Offringa, R. et al. (2000) Recognition of melanomaderived antigens by CTL: Possible mechanisms involved in down-regulating anti-tumor T-cell reactivity. Current Opinion in Immunology 12, 576
13. Wang, Z. et al. (1999) Selective histocompatibility leukocyte antigen (Hla)-A2 loss caused by aberrant pre-mRNA splicing in 624mel28 melanoma cells. Journal of Experimental Medicine 190, 205-216
14. Welsh, R.M., Selin, L.K. and Szomolanyi-Tsuda, E. (2004) Immunological memory to viral infections. Annual Review of Immunology 22, 711-743 (Pubitemid 38680439)
15. Boshkov, L.K., Macen, J.L. and Mcfadden, G. (1992) Virus-induced loss of class I MHC antigens from the surface of cells infected with myxoma virus and malignant rabbit fibroma virus. Journal of Immunology 148, 881-887
16. Miller, D.M. and Sedmak, D.D. (1999)Viral effects on antigen processing. Current Opinion in Immunology 11, 94-99 (Pubitemid 29082344)
17. Andersen, P.S. et al. (1996) A recombinant antibody with the antigen-specific, major histocompatibility complex-restricted specificity of T cells. Proceedings of the National Academy of Sciences of the United States of America 93, 1820-1824 (Pubitemid 26079838)
18. Altman, J.D. et al. (1996) Phenotypic analysis of antigen-specific T lymphocytes. Science 4;274, 94-96 (Pubitemid 26332731)
19. Denkberg, G. et al. (2000) Recombinant human single-chain MHC-peptide complexes made from E. coli by in vitro refolding: Functional single-chain MHC-peptide complexes and tetramers with tumor associated antigens. European Journal of Immunology 30, 3522-3532 (Pubitemid 32005224)
20. Garboczi, D.N., Hung, D.T. and Wiley, D.C. (1992) HLA-A2-peptide complexes: Refolding and crystallization of molecules expressed in Escherichia coli and complexed with single antigenic peptides. Proceedings of the National Academy of Sciences of the United States of America 89, 3429-3433
21. Denkberg, G., Cohen, C.J. and Reiter, Y. (2001) Critical role for CD8 in binding of MHCtetramers to TCR: CD8 antibodies block specific binding of human tumor- specific MHC-peptide tetramers to TCR. Journal of Immunology 167, 270-276 (Pubitemid 32567788)
22. Hoogenboom, H.R. (2005) Selecting and screening recombinant antibody libraries. Nature Biotechnology 23, 1105-1116 (Pubitemid 41486392)
23. Chames, P. et al. (2000) Direct selection of a human antibody fragment directed against the tumor T-cellepitope HLA-A1-MAGE-A1 from a nonimmunized phage-Fab library. Proceedings of the National Academy of Sciences of the United States of America 97, 7969-7974 (Pubitemid 30460757)
24. Cohen, C.J. et al. (2003) Recombinant antibodies with MHC-restricted, peptide-specific, T-cell receptorlike specificity: New tools to study antigen presentation and TCR-peptide-MHC interactions. Journal of Molecular Recognition 16, 324-332 (Pubitemid 37231701)
25. Denkberg, G. et al. (2002) Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC- restricted T cell receptor-like specificity. Proceedings of the National Academy of Sciences of the United States of America 99, 9421-9426 (Pubitemid 34764629)
26. Lev, A. et al. (2002) Isolation and characterization of human recombinant antibodies endowed with the antigen-specific, major histocompatibility complexrestricted specificity of T cells directed toward the widely expressed tumor T-cell epitopes of the telomerase catalytic subunit. Cancer Research 62, 3184-3194 (Pubitemid 34602412)
27. Cohen, C.J. et al. (2002) Direct detection and quantitation of a distinct T-cell epitope derived from tumor-specific epithelial cell-associated mucin using human recombinant antibodies endowed with the antigen-specific, major histocompatibility complexrestricted specificity of T cells. Cancer Research 62, 5835-5844 (Pubitemid 35204743)
28. Cohen, C.J. et al. (2003) Direct phenotypic analysis of human MHC class I antigen presentation: visualization, quantitation, and in situ detection of human viral epitopes using peptide-specific, MHCrestricted human recombinant antibodies. Journal of Immunology 170, 4349-4361 (Pubitemid 36428205)
29. Biddison, W.E. et al. (2003) Tax and M1 peptide/ HLA-A2-specific Fabs and T cell receptors recognize nonidentical structural features on peptide/HLA-A2 complexes. Journal of Immunology 171, 3064-3074 (Pubitemid 37093530)
30. 4+ CD25 + T cells detected by peptide-specific, major histocompatibility complex-restricted antibodies in patients with HTLV-I-associated neurologic disease. Journal of Experimental Medicine 199, 1367-1377 (Pubitemid 38685728)
31. Held, G. et al. (2004) Dissecting cytotoxic T-cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments. European Journal of Immunology 34, 2919-2929 (Pubitemid 39430167)
32. De Haard, H.J. et al. (1999) A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies. Journal of Biological Chemistry 274, 18218-18230
33. Griffiths, A.D. et al. (1994) Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO Journal 13, 3245-3260 (Pubitemid 24226939)
34. Chames, P. et al. (2002) TCR-like human antibodies expressed on human CTLs mediate antibody affinity-dependent cytolytic activity. Journal of Immunology 169, 1110-1118 (Pubitemid 34753472)
35. Stewart-Jones, G. et al. (2009) Rational development of high-affinity T-cell receptor-like antibodies. Proceedings of the National Academy of Sciences of the United States of America 106, 5784-5788
36. Krogsgaard, M. et al. (2000) Visualization of myelin basic protein (MBP) T cell epitopes in multiple sclerosis lesions using a monoclonal antibody specific for the human histocompatibility leukocyte antigen (HLA)-DR2-MBP85-99 complex. Journal of Experimental Medicine 191, 1395-1412 (Pubitemid 30227126)
37. Denkberg, G. et al. (2003) Selective targeting of melanoma and APCs using a recombinant antibody with TCR-like specificity directed toward a melanoma differentiation antigen. Journal of Immunology 171, 2197-2207 (Pubitemid 37025524)
38. Dadaglio, G. et al. (1997) Characterization and quantitation of peptide-MHC complexes produced from hen egg lysozyme using a monoclonal antibody. Immunity 6, 727-738 (Pubitemid 27305735)
39. Porgador, A. et al. (1997) Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity 6, 715-726 (Pubitemid 27305734)
40. Sergeeva, A. et al. (2011)Ananti-PR1/HLA-A2 T-cell receptor-like antibody mediates complementdependent cytotoxicity against acute myeloid leukemia progenitor cells. Blood 117, 4262-4272
41. Tamminen, W.L. et al. (1987) Searching for MHCrestricted anti-viral antibodies: Antibodies recognizing the nucleoprotein of influenza virus dominate the serological response of C57BL/6 mice to syngeneic influenza-infected cells. European Journal of Immunology 17, 999-1006 (Pubitemid 17101315)
42. Rubin B, M.B. et al. (1989) Recognition of insulin on MHC-class-II-expressing L929 cells by antibody and T cells. Research in Immunology 140, 67-74
43. Wittman, V.P. et al. (2006) Antibody targeting to a class I MHC-peptide epitope promotes tumor cell death. Journal of Immunology 177, 4187-4195 (Pubitemid 44359954)
44. Sastry, K.S.R. et al. (2011) Targeting hepatitis B virusinfected cells with a T-cell receptor-like antibody. Journal of Virology 85, 1935-1942
45. Herschhorn, A., Marasco, W.A. and Hizi, A. (2010) Antibodies and lentiviruses that specifically recognize a T cell epitope derived from HIV-1 Nef protein and presented by HLA-C. Journal of Immunology 185, 7623-7632
46. Bernardeau, K et al. (2005) Assessment of CD8 involvement in T cell clone avidity by direct measurement of HLA-A2/Mage3 complex density using a high-affinity TCR like monoclonal antibody. European Journal of Immunology 35, 2864-2875 (Pubitemid 41555082)
47. Verma, B. et al. (2010) TCR mimic monoclonal antibody targets a specific peptide/HLA class I complex and significantly impedes tumor growth in vivo using breast cancer models. Journal of Immunology 184, 2156-2165
48. Makler, O. et al. (2010) Direct visualization of the dynamics of antigen presentation in human cells infected with cytomegalovirus revealed by antibodies mimicking TCR specificity. European Journal of Immunology 40, 1552-1565
49. Bronner, V. et al. (2010) Therapeutic antibodies: Discovery and development using the ProteOn XPR36 biosensor interaction array system. Analytical Biochemistry 406, 147-156
50. Michaeli,Y. et al. (2009) Expression hierarchy of Tcell epitopes from melanoma differentiation antigens: unexpected high level presentation of tyrosinase-HLA-A2 complexes revealed by peptide-specific, mhc-restricted, TCR-like antibodies. Journal of Immunology 182, 6328-6341
51. Denkberg, G. et al. (2002) Modification of a tumorderived peptide at an HLA-A2 anchor residue can alter the conformation of the MHC-peptide complex: Probing with TCR-like recombinant antibodies. Journal of Immunology 169, 4399-4407 (Pubitemid 35178214)
52. Klechevsky, E. et al. (2008) Antitumor activity of immunotoxins with T-cell receptor-like specificity against human melanoma xenografts. Cancer Research 68, 6360-6367
53. Cloutier, S.M. et al. (2000) Streptabody, a high avidity molecule made by tetramerization of in vivo biotinylated, phage display-selected scFv fragments on streptavidin. Molecular Immunology 37, 1067-1077 (Pubitemid 32786719)
54. Kawakami, Y. et al. (2000) Recognition of shared melanoma antigens in association with major HLAA alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma. Journal of Immunotherapy 23, 17-27 (Pubitemid 30079822)
55. Kawakami, Y. et al. (1994) Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. Journal of Experimental Medicine 180, 347-352 (Pubitemid 24181083)
56. Romero, P. et al. (2002) Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunological Reviews 188, 81-96 (Pubitemid 35398867)
57. Oved, K. et al. (2007)Anovel postpriming regulatory check point of effector/memory T cells dictated through antigen density threshold-dependent anergy. Journal of Immunology 178, 2307-2317 (Pubitemid 46233429)
58. Taams, L.S., Van Eden, W. and Wauben, M.H.M. (1999) Dose-dependent induction of distinct anergic phenotypes: Multiple levels of T cell anergy. Journal of Immunology 162, 1974-1981 (Pubitemid 29288814)
59. Weidanz, J.A. et al. (2006) Levels of specific peptide- HLA class I complex predicts tumor cell susceptibility to CTL killing. Journal of Immunology 177, 5088-5097 (Pubitemid 44527579)
60. Nunoya, J. et al. (2009) Short communication: generation of recombinant monoclonal antibodies against an immunodominant HLA-A*2402- restricted HIV type 1 CTL epitope. AIDS Research and Human Retroviruses 25, 897-904
61. 4+ CD25+ T Cells detected by peptide-specific, major histocompatibility complex-restricted antibodies in patients with HTLV-I-associated neurologic disease. Journal of Experimental Medicine 199, 1367-1377 (Pubitemid 38685728)
62. Weiner, L.M., Surana, R. and Wang, S. (2010) Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nature Reviews Immunology 10, 317-327
63. Cartron, G. et al. (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc3?RIIIa gene. Blood 99, 754-758 (Pubitemid 34525533)
64. Clynes, R.A. et al. (2000) Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nature Medicine 6, 443-446 (Pubitemid 30208162)
65. Verma, B. et al. (2011) TCR mimic monoclonal antibodies induce apoptosis of tumor cells via immune effector-independent mechanisms. Journal of Immunology 186, 3265-3276
66. Edwards, M.S. et al. (2012) A systematic review of treatment guidelines for metastatic colorectal cancer. Colorectal Disease 14, e31-e47
67. Choudhary, S., Mathew, M. and Verma, R.S. (2011) Therapeutic potential of anticancer immunotoxins. Drug Discovery Today 16, 495-503
68. Epel, M. et al. (2008) Targeting TARP, a novel breast and prostate tumor-associated antigen, with T cell receptor-like human recombinant antibodies. European Journal of Immunology 38, 1706-1720
69. Berntsen, A., Geertsen, P.F. and SVane, I.M. (2006) Therapeuticdendritic cellvaccinationofpatients with renal cell carcinoma. European Urology 50, 34-43 (Pubitemid 43850125)
70. Jähnisch, H. et al. (2010) Dendritic cell-based immunotherapy for prostate cancer. Clinical and Developmental Immunology 2010, 517493
71. Zehn, D. et al. (2004) Extended presentation of specific MHC-peptide complexes by mature dendritic cells compared to other types of antigenpresenting cells. European Journal of Immunology 34, 1551-1560 (Pubitemid 39256036)
72. Neethling, F.A. et al. (2008) Assessing vaccine potency using TCRmimic antibodies. Vaccine 26, 3092-3102
73. Topalian, S.L. and Rosenberg, S.A. (1989) Tumorspecific cytolysis by lymphocytes infiltrating human melanomas. Journal of Immunology 142, 3714-3725 (Pubitemid 19137511)
74. Hong, J.J. et al. (2010) Successful treatment of melanoma brain metastases with adoptive cell therapy. Clinical Cancer Research 16, 4892-4898
75. Eshhar, Z. et al. (2001) Functional expression of chimeric receptor genes in human T cells. Journal of Immunological Methods 248, 67-76 (Pubitemid 32167025)
76. Stauss, H.J. et al. (2007) Monoclonal T-cell receptors: New reagents for cancer therapy. Molecular Therapy 15, 1744-1750 (Pubitemid 47434180)
77. Pule, M.A. et al. (2008) Virus-specific T cells engineered to coexpress tumor-specific receptors: Persistence and antitumor activity in individuals with neuroblastoma. Nature Medicine 14, 1264-1270
78. Willemsen, R.D. et al. (2001) A phage display selected Fab fragment with MHC class I-restricted specificity for MAGE-A1 allows for retargeting of primary human T lymphocytes. Gene Therapy 8, 1594-1600
79. Willemsen, R.A. et al. (2005) T cell retargeting with MHC class I-restricted antibodies: The CD28 costimulatory domain enhances antigen-specific cytotoxicity and cytokine production. Journal of Immunology 174, 7853-7858 (Pubitemid 40806294)
80. Schmid, D.A. et al. (2010) Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. Journal of Immunology 184, 4936-4946
81. Khan, I.A. et al. (2000) IP-10 is critical for effector T cell trafficking and host survival in Toxoplasma gondii infection. Immunity 12, 483-494
82. Corti, D. et al. (2011) A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza a hemagglutinins. Science 333, 850-856
83. Mimura, K. et al. (2005) Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma. Clinical Cancer Research 11, 4898-4904 (Pubitemid 41557210)
84. Weidanz, J.A. et al. (2007) Development and implementation of a direct detection, quantitation and validation system for class I MHC self-peptide epitopes. Journal of Immunological Methods 318, 47-58 (Pubitemid 46026805)